Newron Pharmaceuticals Highlights 2024 Investor Day in NYC

Newron Pharmaceuticals held its 2024 Investor Day in New York City, showcasing the potential of its investigational drug, evenamide, for treatment-resistant schizophrenia (TRS). Leading schizophrenia experts underscored evenamide's unique mechanism in addressing core abnormalities, including reducing hippocampal dopaminergic activity to improve psychosis, social interactions, and cognition.

Clinical evidence indicated that 25% of patients achieved remission with evenamide as an add-on therapy, suggesting its long-term benefits for TRS. The event featured insights from noted scholars on the unmet medical needs in schizophrenia and the potential impact of evenamide's Phase III clinical trials to further establish its efficacy and safety.

Stefan Weber, CEO of Newron Pharmaceuticals, emphasized the drug’s blockbuster potential if approved, while outlining ongoing efforts to partner for the completion of its Phase III development.